News
Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt ...
5d
GlobalData on MSNAlvotech expands biosimilars capabilities with Ivers-Lee acquisitionIvers-Lee’s assembly and packaging capabilities will be integrated into Alvotech's Technical Operations division.
Linda Jónsdóttir Linda Jonsdottir, Alvotech's new Chief Financial Officer REYKJAVIK, ICELAND (July 10, 2025) — Alvotech ...
Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches.
Alvotech, a global biotech company specializing in the development and manufacture of biosimilars, has appointed Linda ...
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech ...
21d
Pharmaceutical Technology on MSNBayer’s Eylea market grip set to slip as Alvotech biosimilar closes inAn EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.
Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...
Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down. He will continue supporting Alvotech in an advisory capacity to ensure a smooth transition.
— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global ...
Hosted on MSN20d
Alvotech (ALVO): A Bull Case Theory - MSNAlvotech (ALVO)’s share was trading at $10.37 as of 10th June. ALVO’s trailing and forward P/E were 28.73 and 52.91 respectively according to Yahoo Finance. Alvotech is a vertically integrated ...
REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results